Grainger VIP Impact Report

A notable advancement in our research has been a move to develop allogeneic “off-the-shelf” cell therapies alongside storage-stable nanoparticle formulations. These innovations are set to increase the accessibility of cell and gene therapy products, potentially revolutionizing how these treatments are delivered and experienced by patients worldwide. The support from nationally recognized centers, the CMaT and the Somatic Cell Genome Editing Consortium, has been invaluable. Their belief in our work has propelled us closer to our goal of submitting Investigational New Drug Applications for cellular immunotherapies for cancer and injectable gene therapies for retinal disorders. As we look to the future, the continued support from The Grainger Foundation will be crucial in our quest to improve patient health, not only within Wisconsin’s borders but also across the globe.

28

WISCONSIN FOUNDATION AND ALUMNI ASSOCIATION | 608-263-4545 | SUPPORTUW.ORG